ES2166778T3 - Factor de crecimiento ii de tipo insulina como agente antitumoral. - Google Patents

Factor de crecimiento ii de tipo insulina como agente antitumoral.

Info

Publication number
ES2166778T3
ES2166778T3 ES94915218T ES94915218T ES2166778T3 ES 2166778 T3 ES2166778 T3 ES 2166778T3 ES 94915218 T ES94915218 T ES 94915218T ES 94915218 T ES94915218 T ES 94915218T ES 2166778 T3 ES2166778 T3 ES 2166778T3
Authority
ES
Spain
Prior art keywords
pct
growth factor
insulin type
medicament
antitumoral agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94915218T
Other languages
English (en)
Inventor
Paul Schofield
Robert Charles Rees
Anna Skottner-Lundin
Amardip Singh Departme Bhuller
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cancer Research Campaign Technology Ltd
Swedish Orphan Biovitrum AB
Original Assignee
Cancer Research Campaign Technology Ltd
Biovitrum AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Research Campaign Technology Ltd, Biovitrum AB filed Critical Cancer Research Campaign Technology Ltd
Application granted granted Critical
Publication of ES2166778T3 publication Critical patent/ES2166778T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors (Somatomedins), e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LA INVENCION SE REFIERE AL USO DE IGF-II PARA LA FABRICACION DE UN MEDICAMENTO PARA EL TRATAMIENTO DE TUMORES, Y ESPECIALMENTE PARA LA FABRICACION DE UN MEDICAMENTO PARA LA INHIBICION DEL CRECIMIENTO DE LAS CELULAS DEL MELANOMA Y PARA EL TRATAMIENTO DE MELANOMAS CUTANEOS. EL MEDICAMENTO PUEDE SER ADMINISTRADO SISTEMATICAMENTE O LOCALMENTE.
ES94915218T 1993-05-12 1994-05-12 Factor de crecimiento ii de tipo insulina como agente antitumoral. Expired - Lifetime ES2166778T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB939310049A GB9310049D0 (en) 1993-05-12 1993-05-12 Growth factor effects

Publications (1)

Publication Number Publication Date
ES2166778T3 true ES2166778T3 (es) 2002-05-01

Family

ID=10735556

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94915218T Expired - Lifetime ES2166778T3 (es) 1993-05-12 1994-05-12 Factor de crecimiento ii de tipo insulina como agente antitumoral.

Country Status (13)

Country Link
US (1) US5902788A (es)
EP (1) EP0697885B1 (es)
JP (1) JPH08510230A (es)
AT (1) ATE205398T1 (es)
AU (1) AU682862B2 (es)
CA (1) CA2162594A1 (es)
DE (1) DE69428276T2 (es)
DK (1) DK0697885T3 (es)
ES (1) ES2166778T3 (es)
GB (1) GB9310049D0 (es)
NZ (1) NZ265994A (es)
PT (1) PT697885E (es)
WO (1) WO1994026300A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6630168B1 (en) 1997-02-20 2003-10-07 Biomedicines, Inc. Gel delivery vehicles for anticellular proliferative agents

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE116335T1 (de) * 1987-12-24 1995-01-15 Gropep Pty Ltd Peptid-analoge vom insulinähnlichen wachstums- faktor 1 (igf-1) oder faktor 2 (igf-2).
SE9101341D0 (sv) * 1991-05-03 1991-05-03 Kabi Pharmacia Ab New medicinal use
US5202119A (en) * 1991-06-28 1993-04-13 Genentech, Inc. Method of stimulating immune response

Also Published As

Publication number Publication date
NZ265994A (en) 2001-02-23
AU6654794A (en) 1994-12-12
EP0697885A1 (en) 1996-02-28
EP0697885B1 (en) 2001-09-12
ATE205398T1 (de) 2001-09-15
CA2162594A1 (en) 1994-11-24
JPH08510230A (ja) 1996-10-29
DE69428276D1 (de) 2001-10-18
DE69428276T2 (de) 2002-05-16
WO1994026300A1 (en) 1994-11-24
US5902788A (en) 1999-05-11
GB9310049D0 (en) 1993-06-30
AU682862B2 (en) 1997-10-23
DK0697885T3 (da) 2001-12-31
PT697885E (pt) 2002-03-28

Similar Documents

Publication Publication Date Title
MXPA03003960A (es) Combinaciones de farmacos (v.gr., clorpromazina y pentamidina) para el tratamiento de desordenes neoplasticos.
NO954996D0 (no) Anvendelse av nona- og dekapeptider for fremstilling av et legemiddel for behandling av AIDS
NO20101190L (no) Anvendelse av buprenorfin i fremstillingen av et medikament
CO4290346A1 (es) Formas de dosificacion de liberacion controlada de azitromicina
SE9702860D0 (sv) New use
PT671910E (pt) Utilizacao de derivados de adamantano no fabrico de um medicamento para o tratamento do glaucoma
PT1161248E (pt) Composição farmacêutica que contém uma fonte de nitrato e um agente acidificante destinada ao tratamento de feridas abertas e queimaduras
ES2136723T3 (es) Utilizacion de n-aril-metilen-etilen-diamino-triacetatos, n-aril-metilen-imino-diacetatos o n,n'-diaril-metilen-etilen-diamino-acetatos contra el estres oxidante.
ATE495793T1 (de) Antitumorzusammensetzungen welche ecteinascidin 743 enthalten
PL329802A1 (en) Derivatives of androstene
BG106171A (en) Compositions and uses of et743 for treating cancer
BG106057A (en) Method of enhancing the efficacy of anti-tumour agents
SE9701161D0 (sv) New use I
HK1047707A1 (zh) (+)-曲馬朵、o-去甲曲馬朵或(+)-o-去甲曲馬朵、o-去甲-n-單-去甲-曲馬朵或(+)-o-去甲-n-單-去甲-曲馬朵治療尿失禁的用途
DE60115432D1 (de) Apoptotische körper zur verwendung in der behandlung von t-zell-vermittelten- und entzündungserkrankungen
DE69821498D1 (de) Verwendung von amifostin
BR0214196A (pt) Método e composição para reduzir a atividade de inibir o crescimento de uma célula cancerosa, para tratar de paciente com câncer
HK1029932A1 (en) Use of mirtazapine for the manufacture of a medicament for treating sleep apneas.
RS52011B (sr) Nova primena derivata taksoida
AU1795101A (en) Safety mechanism to prevent accidental patient injection and methods of same
ES2166778T3 (es) Factor de crecimiento ii de tipo insulina como agente antitumoral.
GEP20043231B (en) Resorcinol Composition
AU6432899A (en) Use of metformin to counteract weight gain associated with valproate and other psychotropic medications
ATE293983T1 (de) Verwendung von n-acetyl-d-glucosamin bei der herstellung eines arzneimittels zur unterdrückung der nebenwirkungen von strahlentherapie und chemotherapie
ES2110104T3 (es) Procedimiento para la administracion de soluciones de factor de estimulacion de las colonias de granulocitos.